Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
Status:
Recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable
esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with
camrelizumab and achieved clinical complete remission with watchful waiting strategy.